Provide full-process services from antibody design to large-scale production

CONTACT

Synthetic phage display platform

Constream Biotech currently has a library capacity of 10 ¹¹of the fully human Fab synthetic library. The ultimate goal is to establish a 100-billion-level fully human Fab synthetic library, committed to developing high-affinity, high-specificity candidate antibodies for pharmaceutical companies and diagnostic reagent companies.

Fully human heavy chain synthetic library

The fully human single-chain antibody library combines the low immunogenicity of fully human antibodies with the high permeability of single-chain structures. It is an important tool for developing the next generation of therapeutic antibodies (especially solid tumor-targeted drugs), and provides a rapid screening platform for personalized medicine.

Antibody discovery

Rabbit monoclonal antibody technology platform

Constream Biotech - Phage Display Technology × Rabbit Monoclonal Antibody Development, Unlocking New Potential for High-Affinity Antibodies

Single B cell screening technology platform

Single B cell antibody screening technology is an innovative method to obtain specific antibodies quickly through screening, amplification, and cloning of single B cells. This technology can directly obtain antibody information from the immunized body, avoiding the cumbersome steps of cell culture and hybridoma establishment in traditional screening technologies, thus greatly improving the efficiency and accuracy of antibody screening.

Nanobody discovery platform

Llama-derived nanobodies (VHH antibodies or single-domain antibodies) are single-domain antibodies isolated from the naturally occurring heavy-chain antibodies (HCAbs) found in camelids (such as llamas and camels). With a molecular weight of only approximately 15 kDa, they are the smallest functional antigen-binding units currently known. Their unique structure and biological properties offer immense potential in the fields of biomedicine, diagnostics, and industry.

Hybridoma screening platform

Hybridoma technology is an important monoclonal antibody technology. Based on cell fusion technology, it fuses B lymphocytes from immunized animals with myeloma cells. Through HAT selection and specific screening, and subcloning, monoclonal antibody cell lines that can specifically recognize the target antigen are obtained. The cell lines are cultured in vivo or in vitro, and monoclonal antibodies are obtained after affinity purification.

< 1 >

Protein expression platform

Stable cell line construction

The CHO-K1 host and its accompanying vector are clearly sourced and authorized, originating from the wild-type CHO-K1 cells of the European Collection of Authenticated Cell Cultures (ECACC). The expression vector is pKS001, using glutamine synthetase (GS) as a selection marker, with methionine sulfoximine (MSX) as the selection pressure; electrotransfection is used, with an efficiency of 90% or higher; rich experience in signal peptide optimization, selection marker setting, and codon optimization.

Stable expression and preparation of Pool protein

Expression level: 1-4.0 g/L. Bulkpool preparation: gram-level protein (4-5 weeks). Minipool preparation: 10g-level protein (8-9 weeks).

Large-scale electricity conversion platform

Primarily used in the R&D and preclinical research of macromolecular biopharmaceuticals such as antibodies and recombinant proteins, as well as the production and preparation of IVD antigen and antibody raw materials.

< 1 >

Other services

AI antibody discovery platform

Powered by a large language model intelligent brain, it can complete antibody engineering, generation, structure prediction, design optimization and modification, and wet experiment verification in one stop.

Custom development of ADA antibodies

Immunogenicity of a drug refers to its ability, and/or that of its metabolites, to induce an immune response or immune-related event against itself or related proteins. With the increasing research and development of new drugs, especially therapeutic protein drugs, in China, research related to immunogenicity is becoming increasingly widespread.

CHO cell HCP customized development

Constream Biotech can provide customized development services for broad-spectrum or specific HCP reagents targeting different CHO cells (CHO-K1, CHO-S, CHO-DG44, etc.).

Monoclonal antibody preparation of ADC payload

ADC drugs are multi-domain molecules composed of monoclonal antibodies (mAbs), linkers, and small molecule cytotoxins. With the increasing number of ADC drugs, the clinical immunogenicity risk of ADC drugs has been increasingly valued by the industry. The design and development of neutralizing antibody detection methods for ADC drugs are different from those of conventional antibody drugs and present significant challenges.

< 1 >

Antibody engineering transformation

Antibody engineering

Antibody humanization

In antibody drug development, reducing immunogenicity while preserving targeting ability is a core challenge for clinical translation.Constream Biotech, with its CDR grafting antibody humanization technology, provides scientific solutions for global customers, helping to achieve breakthroughs in both safety and efficacy of antibody drugs!

Affinity maturation of antibodies

Constream Biotech focuses on antibody engineering innovation. Leveraging an international phage display technology platform, we provide antibody affinity maturation services to global clients. By constructing high-diversity mutant libraries and combining intelligent screening strategies, we can rapidly optimize antibody affinity and specificity, accelerating breakthroughs in therapeutic antibody, diagnostic reagent, and biopharmaceutical R&D.

< 1 >

Rapid Druggability Analysis

Rapid analysis of the efficacy of ready-made medicines

Constream Biotech has extensive experience in assessing the druggability of various new molecules such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), protein engineering, candidate molecule construction and expression, and in vitro efficacy evaluation. This allows for effective bridging between new drug R&D and CMC pharmaceutical development, facilitating the advancement of superior molecules to the next stage of development.

< 1 >

Subscription Information

We will send you real-time information regularly!

Email:

taoweihong@constreambio.com

Shanghai Constream biotechnology Co., Ltd.

Tel: 021-59255902

Address: 3rd Floor, Building 28, No. 10688, Beiqing Highway, Qingpu District, Shanghai

Mobile Website

Official Account

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Provide full-process services from antibody design to large-scale production

Technical services

Subscription Information

COOKIES

COOKIES